Maureen Canavan, PhD, MPH
Associate Research Scientist (General Medicine)Cards
About
Titles
Associate Research Scientist (General Medicine)
Affiliated Faculty, Yale Institute for Global Health
Biography
Maureen E. Canavan, Ph.D., is an epidemiologist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) since 2017. In addition to working the MCBS data, she works as part of the Yale Cancer Center’s Cancer Care Innovations Lab (CaCIL) team evaluating quality metrics for cancer care. Her research interests include health management, employment, and end of life care. Prior to her work at COPPER, she was a member of the Global Health Leadership Institute (GHLI) team, she conducts qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China. She received an M.P.H. from the University of Medicine and Dentistry of New Jersey, School of Public Health and a B.S. from Pennsylvania State University.
Last Updated on May 21, 2025.
Appointments
General Internal Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
- All Institutions
- COPPER Center
- General Internal Medicine
- Internal Medicine
- Obesity Research Working Group
- Yale Institute for Global Health
Education & Training
- PhD
- Yale University Graduate School (2011)
- MPH
- University of Medicine and Dentistry of New Jersey, School of Public Health, Epidemiology, Health Education, and Behavioral Science (2005)
- BS
- Pennsylvania State University, Biology (2003)
Research
Publications
2026
Updated Review: Using the National Cancer Database for Outcomes-Based Research.
Ayoade O, Caturegli G, Palis B, McCabe R, Weigel R, Canavan M, Boughey J, Boffa D. Updated Review: Using the National Cancer Database for Outcomes-Based Research. Journal Of The American College Of Surgeons 2026 PMID: 41848188, DOI: 10.1097/xcs.0000000000001924.Peer-Reviewed Original ResearchNational Cancer DatabaseFollow-upNon-small cell lung cancerAmerican CollegeCell lung cancerNarrative reviewCancer Reporting SystemCancer-accredited hospitalsPD-L1Tumor gradeTumor sizeCancer DatabaseContinuous tumor sizeLung cancerSmoking statusOutcomes-based researchOncology practiceSurvival dataMedicaid expansion statusOutcome studiesFollow-up limitCancerTreatment reportsPolicy changesPolicy-relevant dataUse of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original ResearchConceptsCohort studyManagement of breast cancerBreast cancerCohort study of dataMedical management of breast cancerTreated with CAMCox proportional hazards modelsMedical managementYear of diagnosisFemale patientsCombination of CAMProportional hazards modelTraditional therapiesAlternative medicineStudy of dataMain OutcomesEndocrine therapyNo treatmentCharlson Comorbidity IndexInsurance typeNonmedical personnelPrimary outcomeFacility typeSurvival timeHazards model
2025
Impact of a standardized multi-level review of anti-cancer therapy ordered for hospitalized individuals with solid tumors.
Westvold S, Shevlin C, Canavan M, Strait M, Abdelghany O, Carafeno T, Flanagan B, Merl M, Mitchell T, Carusillo N, Morris J, Gross C, Huntington S. Impact of a standardized multi-level review of anti-cancer therapy ordered for hospitalized individuals with solid tumors. JCO Oncology Practice 2025, 21: 477-477. DOI: 10.1200/op.2025.21.10_suppl.477.Peer-Reviewed Original ResearchSystemic anti-cancer therapyEnd-of-lifeDay of deathBedside nursing assessmentHospitalized patientsProportion of decedentsAnti-cancer therapySolid tumorsQuality of lifeNursing assessmentPhysician reviewPoisson regressionBenefits of treatmentCommittee reviewFisher's exact testPatient daysOrder rateSolid tumor patientsTreatment risksDecedentsExact testPhysiciansPharmacyTime periodsPatientsAssociation of systemic anticancer treatment (SACT) with end-of-life (EOL) healthcare use among older patients with hematologic malignancies.
Xiang J, Cheng L, Canavan M, Lin J, Hui D, Ratan R, Flowers C, Niu J, Zhao H, Giordano S, Adelson K. Association of systemic anticancer treatment (SACT) with end-of-life (EOL) healthcare use among older patients with hematologic malignancies. JCO Oncology Practice 2025, 21: 306-306. DOI: 10.1200/op.2025.21.10_suppl.306.Peer-Reviewed Original ResearchEnd-of-lifeAcute care useDay of deathHospice useTargeted therapyHealthcare useCare useHematological cancersOlder patientsEnd-of-life careEnd-of-life outcomesICU useHigh healthcare useAssociated with lower qualityER visitsAssociated with higher oddsAnticancer treatmentAssociated with significantly higher ratesQuality of lifeEOL careMultivariate logistic regressionEOL outcomesMonths of lifeChi-square testSignificantly higher ratesP1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2025, 20: s148-s149. DOI: 10.1016/j.jtho.2025.09.274.Peer-Reviewed Original ResearchP2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy. Journal Of Thoracic Oncology 2025, 20: s343. DOI: 10.1016/j.jtho.2025.09.643.Peer-Reviewed Original ResearchAssociation Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality
Canavan M, Cheng L, Xiang J, Lin J, Hui D, Zhao H, Nortje N, Ratan R, Cherny N, Pham T, Giordano S, Niu J, Adelson K. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. Journal Of Clinical Oncology 2025, 43: 3391-3402. PMID: 41004691, DOI: 10.1200/jco-25-00530.Peer-Reviewed Original ResearchThis study investigates the impact of systemic anticancer therapy near the end of life on healthcare and hospice for older adults, showing increased acute care utilization and decreased hospice use, highlighting the need for improved end-of-life care guidelines.Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer. JTCVS Open 2025, 28: 554-564. PMID: 41473080, PMCID: PMC12745116, DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsMortality Risk and Cause of Death Associated With Removal of the Adult Thymus: Analysis of the U.S. Thymoma Population
Resio B, Canavan M, Caturegli G, Detterbeck F, Boffa D. Mortality Risk and Cause of Death Associated With Removal of the Adult Thymus: Analysis of the U.S. Thymoma Population. Journal Of Thoracic Oncology 2025, 21: 186-194. PMID: 40865907, DOI: 10.1016/j.jtho.2025.08.017.Peer-Reviewed Original ResearchSurveillance Epidemiology and End ResultsNational Cancer DatabaseDuctal carcinoma in situPropensity-matched patientsThyroid cancerAdult thymusU.S. populationImmunologic end pointsCarcinoma in situFive-year survivalCancer incidencePartial thymectomyThyroid lobectomyResected breastLonger-term outcomesPartial mastectomyThyroid neoplasmsTotal thymectomyCancer DatabaseCause of deathNo significant differenceSecondary cancersSmall thymomaThymectomyEnd ResultsHypertensive Disorders of Pregnancy and Breastfeeding Among US Women
Nardella D, Canavan M, Taylor S, Sharifi M. Hypertensive Disorders of Pregnancy and Breastfeeding Among US Women. JAMA Network Open 2025, 8: e2521902. PMID: 40679825, PMCID: PMC12274979, DOI: 10.1001/jamanetworkopen.2025.21902.Peer-Reviewed Original ResearchConceptsPrevention's Pregnancy Risk Assessment Monitoring SystemAssociated with higher oddsBreastfeeding cessationCross-sectional studyPostpartum womenHypertensive disordersHigher oddsSelf-reported high blood pressurePregnancy Risk Assessment Monitoring SystemCenters for Disease Control and Prevention's Pregnancy Risk Assessment Monitoring SystemBreastfeeding support strategiesFirst-time mothersHypertensive disorders of pregnancyMedian timeHigh blood pressureHealth covariatesDisorders of pregnancyBreastfeeding initiationMother-infant dyadsMain OutcomesBreastfeeding outcomesMedicaid insuranceSupport strategiesBreastfeedingComplete data
Academic Achievements & Community Involvement
News
News
- January 08, 2026Source: JCO Podcast
Podcast: Association Between EOL SACT and Healthcare Utilization
- October 22, 2025Source: Cure
Improving End-of-Life Care: Making Hospice and Home Support Accessible
- May 28, 2025
United by Cancer Research: One Mission. One Voice
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO